A Study of the CD73 Inhibitor LY3475070 Alone or in Combination With Pembrolizumab in Participants With Advanced Cancer

J2I-MC-JZMA -

The reason for this study is to see if the CD73 inhibitor LY3475070 alone or in combination with pembrolizumab is safe and effective in participants with advanced cancer.

Trial Summary

Age Range
≥18 years
Conditions the trial is for
Advanced Cancer
What the trial is testing?
LY3475070, Pembrolizumab
Could I receive a Placebo?
No
Enrollment Goal
52
Trial Dates
Jan 16, 2020 - Jun 20, 2022
How long will I be in the trial?
Your participation in this trial could last up to 2 years, depending on your cancer type and how you and your tumor responds.
Trial Phase
I

Key Requirements

Clinical trials have inclusion and exclusion requirements to determine which individuals qualify for participation. Listed below are key requirements for this clinical trial, but there may be additional requirements to qualify.

Participants Must:

  • Participants must have certain types of cancer such as breast cancer, pancreatic cancer, lung cancer, kidney cancer, skin cancer (melanoma), prostate cancer, and ovarian cancer

  • Participants must have stopped other forms of treatment for the cancer

  • Participants must be able and willing to provide a sample of the tumor before beginning treatment and a sample during the treatment. for certain tumor types, the result of a test on the tumor sample may exclude the participant from the study

  • Participants must have progressed through or be intolerant to therapies with known clinical benefit

Participants Must Not:

  • Participants must not be pregnant, and must agree to use birth control

  • Participants must not have a current untreated tuberculosis, lung disease, heart disease, uncontrolled HIV, autoimmune disease, active hepatitis B or C virus infection or using corticosteroids

  • Participant must not have cancer that has spread to the brain

  • Participant must not have received a vaccine within the last 30 days

  • Participant must not have had bowel obstruction within the last 6 months, or intestinal surgery

  • Participant must not have an infection that is currently being treated

Lilly Trial Alerts

Not the right fit? Sign up to receive updates about new trials that are listed or when a new trial site begins enrolling near you.

Clinical Trial Resources

Cancer Research

Lilly has been involved in cancer research for more than fifty years, working to improve the lives of people living with cancer. Learn more about cancer research at Lilly and how you can make an impact.

Learn More

Learn About Our Early and Metastatic Breast Cancer Research

With the help of research study participants, we are learning potential new ways to improve Breast Cancer health outcomes.

Learn More

Prostate Cancer Research

By volunteering to take part in Prostate cancer clinical trials, you may be able to play an important role in the research and development of potential new treatments and medicines. We understand that when you or a loved one take part in a clinical trial, it is a big decision. It is important for you to understand why the research is being carried out and what taking part will mean for you. Learn more about Lilly

Prostate Cancer Research

Clinical Trial Participation: What to Expect

A clinical trial is a scientific study. It helps us learn if a new medicine or treatment works and how it works. Clinical trials can also be called clinical research studies. Learn more about clinical research studies and what to expect when taking part in a clinical trial.